SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 03, 2022 for Shanghvi Finance Pvt Ltd SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find enclosed intimation of Loss of Share Certificates
Buy Sun Pharma; target of Rs 1000: Motilal Oswal
Motilal Oswal is bullish on Sun Pharma recommended buy rating on the stock with a target price of Rs 1000 in its research report dated February 01, 2022.
Buy Sun Pharmaceutical Industries: target of Rs 1000: Sharekhan
Sharekhan is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1000 in its research report dated January 31, 2022. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Submission of Newspaper advertisement under Regulation 30 read with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Fixes Record Date for Interim Dividend
Sun Pharmaceutical Industries Ltd has informed BSE that the Company has fixed February 10, 2022 as the Record Date for the purpose of Payment of Interim Dividend.The payment of the interim dividend would be made to the eligible shareholders on or before February 22, 2022.
Earnings Call for Q3FY22 of Sun Pharmaceutical Industries
Conference Call with Sun Pharmaceutical Industries Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript. Q3FY22 Quarterly Result Announced for Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries declares Q3FY22 result: Consolidated sales from operations at Rs 98,142 million, growth of 11% over Q3 last year India formulation sales at Rs 31,676 million, up 15% over same quarter last year US formulation sales at US$ 397 million, growth of 6% over Q3 last year Emerging Markets formulation sales at US$ 239 million, up by 17% over Q3 last year Rest of World formulation sales at US$ 181 million, up by 3% over same quarter last year R&D; investments at Rs. 5,471 million compared to Rs 5,595 million for Q3FY21 EBITDA at Rs 25,574 million, up by about 8% over Q3 last year, with EBITDA margin at 26.1% Net profit for the quarter was at Rs 20,588 million, up 11% YoY Consolidated sales from operations at Rs 290,403 million, growth of 17% over same period last year. India formulation sales at Rs. 96,637 million, up by 26% over 9m last year. US formulation sales at US$ 1,138 million up by 15% over 9m last year. Emerging Markets formulation sales at US$ 700 million up by 19% over 9m last year. Rest of World formulation sales at US$ 554 million, up by 12% over 9m last year. EBITDA at Rs. 78,900 million up about 27% over 9m last year, with EBITDA margin at 27.2%. Excluding the exceptional items, adjusted net profit for 9mFY22 was at Rs. 60,851 million, up about 33% YoY. Reported net profit for 9MFY22 was at Rs 55,500 million compared to Rs. 20,097 million for 9m last year. Dilip Shanghvi, Managing Director of the Company said, “We achieved a sustained momentum and good growth across businesses; despite rising costs, we have achieved higher profitability. Our India business continues to grow faster than market, leading to increase in market share. Our global specialty business for the first nine months has already crossed previous full-year revenues. We remain steadfast in our focus on topline growth, operational efficiencies and business continuity while simultaneously continuing to expand our global specialty presence.” Result PDF SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release relating to financial results for the third quarter and nine month ending December 31st, 2021. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Appointment of Company Secretary and Compliance Officer
Change in the Company Secretary & Compliance Officer of the Company